Thrombolytic therapy for evolving myocardial infarction needs an approach that integrates benefit and risk

Area of Science:

• Cardiology
• Medical Decision Making

Background:

• Thrombolytic therapy is crucial for acute myocardial infarction (AMI), reducing mortality.
• Current treatment decisions are challenging due to variable patient benefits and bleeding risks, particularly intracranial bleeding.
• Less than half of eligible AMI patients receive thrombolytic therapy.

Purpose of the Study:

• To develop a systematic approach for the 'treat or not to treat' decision in AMI.
• To integrate estimated patient benefit and intracranial bleeding risk into a decision-making model.
• To provide precise thresholds for treatment selection based on risk factors and treatment delay.

Main Methods:

• Development of a decision-model using current medical knowledge.
• Integration of estimated benefits of thrombolytic therapy.
• Inclusion of intracranial bleeding risk factors and cardiac baseline risk.

Main Results:

• Thrombolytic therapy is beneficial for most AMI patients with ST-segment elevation treated within 12 hours.
• Treatment is recommended even with low cardiac death risk (2.3%) if no intracranial hemorrhage risk factors exist.
• For high bleeding risk patients, baseline cardiac risk and treatment delay are critical factors.

Conclusions:

• A systematic decision-model can optimize thrombolytic therapy use in AMI.
• The model balances therapeutic benefits against bleeding risks for individual patient care.
• This approach aims to improve treatment rates and patient outcomes in acute myocardial infarction.